Pathogenesis of Ovarian Serous Carcinoma as the Basis for Immunologic Directed Diagnosis and Treatment. Project 1 - Molecular Characterization of Ovarian Serous Tumors Developing Along Different Pathways

Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma

The Journal of Pathology ◽

10.1002/path.2659 ◽

2009 ◽

Vol 220 (3) ◽

pp. 392-400 ◽

Cited By ~ 46

Author(s):

Jason Madore ◽

Fengge Ren ◽

Ali Filali-Mouhim ◽

Lilia Sanchez ◽

Martin Köbel ◽

...

Keyword(s):

Serous Carcinoma ◽

Endometrioid Carcinoma ◽

Ovarian Serous Carcinoma

Download Full-text

Cancer Stem Cell–Related Marker NANOG Expression in Ovarian Serous Tumors: A Clinicopathological Study of 159 Cases

International Journal of Gynecological Cancer ◽

10.1097/igc.0000000000001105 ◽

2017 ◽

Vol 27 (9) ◽

pp. 2006-2013 ◽

Cited By ~ 9

Author(s):

Nataša Kenda Šuster ◽

Snježana Frković Grazio ◽

Irma Virant-Klun ◽

Ivan Verdenik ◽

Špela Smrkolj

Keyword(s):

Stem Cell ◽

Cancer Stem Cell ◽

Signal Intensity ◽

Serous Carcinoma ◽

Low Grade ◽

Clinical Parameters ◽

High Grade ◽

Ovarian Serous Carcinoma ◽

Nanog Expression ◽

Serous Tumors

ObjectiveThe objectives of this study were to assess cancer stem cell–related marker NANOG expression in ovarian serous tumors and to evaluate its prognostic significance in relation to ovarian serous carcinoma.MethodsNANOG protein expression was immunohistochemically evaluated in the ovarian tissue microarrays of 20 patients with benign ovarian serous tumors, 30 patients with borderline ovarian serous tumors, and 109 patients with ovarian serous carcinomas, from which 106 were of high-grade and 3 of low-grade morphology Immunohistochemical reaction was scored according to signal intensity and the percentage of positive cells in tumor samples. Pursuant to our summation of signal intensity and positive cell occurrence, we divided our samples into 4 groups: NANOG-negative, NANOG–slightly positive, NANOG–moderately positive, and NANOG–strongly positive group. Complete clinical data were obtained for the ovarian serous carcinoma group, and correlation between clinical data and NANOG expression was analyzed.ResultsA specific brown nuclear, or cytoplasmic reaction, was considered a positive NANOG staining. In terms of the ovarian serous carcinoma group, 69.7% were NANOG positive, 22.9% slightly positive, 22.9% moderately positive, and 23.9% strongly positive. All NANOG-positive cases were of high-grade morphology. Benign and borderline tumors and low-grade serous carcinomas were NANOG negative. There was no significant correlation between NANOG expression and clinical parameters in terms of the ovarian serous carcinoma group.ConclusionsPositive NANOG expression is significantly associated with high-grade ovarian serous carcinoma and is absent in benign, borderline, and low-grade serous lesions. In our study, there was no correlation between NANOG expression and clinical parameters, including its use in the prognosis of ovarian serous carcinoma.

Download Full-text